Literature DB >> 25872647

Recombinant Salmonella-based CEACAM6 and 4-1BBL vaccine enhances T-cell immunity and inhibits the development of colorectal cancer in rats: In vivo effects of vaccine containing 4-1BBL and CEACAM6.

Chunhui Jin1, Yingying Liu1, Jianhong Zhu1, Tingting Xia1, Baonan Zhang2, Yajun Fei3, Bo Ma4, Jianxin Ye1, Weichang Chen1.   

Abstract

The present study aimed to determine the effect of recombinant Salmonella (SL3261)-based CEACAM6 and 4-1BB ligand (4-1BBL) vaccine on the development of colorectal cancer in rats and the potential immune mechanisms involved. Attenuated Salmonella typhimurium (vaccine strain)‑carrying plasmids pIRES-CEACAM6, pIRES‑4‑1BBL and pIRES-CEACAM6-4-1BBL were constructed. The rats were administered subcutaneous injections of 1,2-dimethyl-hydrazine (DMH) once a week for 18 weeks. Eight weeks after the first injection, the rats were divided into the pIRES/SL3261, pIRES-4-1BBL/SL3261, pIRES-CEACAM6/SL3261 and pIRES-CEACAM6-4-1BBL/SL3261 groups, and fed with corresponding vaccine strains. The rats were then sacrificed, the number of colon tumors were recorded, and the Dukes' stage were evaluated. CD3, CD4, CD8, CD56, FOXP3 and CEACAM6 expression in tumor tissues was determined by immunohistochemical staining. Compared with the expression levels in the pIRES/SL3261 group, similar levels of CD3+, CD8+ and CD56+ expression were identified for the pIRES-CEACAM6/SL3261 group of rats. Additionally, a comparable number of tumors was detected in the pIRES-4-1BBL/SL3261 and pIRES-CEACAM6/SL3261 groups. By contrast, a significantly fewer number of tumors, albeit with a higher density of CD3+CD8+, CD56+ and a lower density of Foxp3+ tumor-infiltrating lymphocyte (TIL) cells was detected in the pIRES-CEACAM6-4-1BBL/SL3261 group of rats. The results indicated that vaccination with recombinant attenuated Salmonella harboring the CEACAM6 and 4-1BBL gene efficiently increased the number of CD3+CD8+ TIL and NK cells, decreased the number of FOXP3 cells and inhibited the development of DMH-induced colorectal cancer in rats.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25872647     DOI: 10.3892/or.2015.3901

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  T cell immunity induced by a bivalent Salmonella-based CEACAM6 and 4-1BBL vaccines in a rat colorectal cancer model.

Authors:  Chunhui Jin; Xiaoqing Duan; Yingying Liu; Jianhong Zhu; Ke Zhang; Yuanting Zhang; Tingting Xia; Yajun Fei; Jianxin Ye
Journal:  Oncol Lett       Date:  2017-03-28       Impact factor: 2.967

2.  Intramuscular vaccination targeting mucosal tumor draining lymph node enhances integrins-mediated CD8+ T cell infiltration to control mucosal tumor growth.

Authors:  Jin Qiu; Shiwen Peng; Andrew Yang; Ying Ma; Liping Han; Max A Cheng; Emily Farmer; Chien-Fu Hung; T-C Wu
Journal:  Oncoimmunology       Date:  2018-05-24       Impact factor: 8.110

3.  Efficacy of bivalent CEACAM6/4-1BBL genetic vaccine combined with anti-PD1 antibody in MC38 tumor model of mice.

Authors:  Yuzhen Li; Xiaodan Zhu; Jianliang You; Baonan Zhang; Xiaona Huang; Chunhui Jin
Journal:  Heliyon       Date:  2022-09-28

4.  Dual role of carcinoembryonic antigen-related cell adhesion molecule 6 expression in predicting the overall survival of gastric cancer patients.

Authors:  Mingde Zang; Lei Hu; Shu Cao; Zhiyuan Fan; Li Pang; Jianfang Li; Liping Su; Chen Li; Wentao Liu; Qinlong Gu; Zhenggang Zhu; Min Yan; Bingya Liu
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379

5.  Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment.

Authors:  Tae Heung Kang; Jung Hwa Park; Andrew Yang; Hyun Jin Park; Sung Eun Lee; Young Seob Kim; Gun-Young Jang; Emily Farmer; Brandon Lam; Yeong-Min Park; Chien-Fu Hung
Journal:  Nat Commun       Date:  2020-02-28       Impact factor: 14.919

Review 6.  Bacteria-cancer interactions: bacteria-based cancer therapy.

Authors:  Mai Thi-Quynh Duong; Yeshan Qin; Sung-Hwan You; Jung-Joon Min
Journal:  Exp Mol Med       Date:  2019-12-11       Impact factor: 8.718

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.